ViraCyte LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, reported positive data from a Phase 2 clinical trial evaluating its T-cell immunotherapy product, Viralym-M. The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology.
The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor.
Scientists at the University of Oxford have developed a new method to 3D-print laboratory-grown cells to form living structures. The approach could revolutionize regenerative medicine, enabling the production of complex tissues and cartilage that would potentially support, repair or augment diseased and damaged areas of the body.
How do the multiple different cell types in the blood develop? Scientists have been pursuing this question for a long time. According to the classical model, different developmental lines branch out like in a tree. The tree trunk is composed of stem cells and the branches are made up of various types of progenitor cells that can give rise to a number of distinct cell types. Then it further branches off into the specialized blood cells, i.e., red blood cells, blood platelets and various types of white blood cells that are part of the immune system. In recent years, however, doubts about this model have arisen.
UCLA researchers have discovered a new way to activate the stem cells in the hair follicle to make hair grow. The research, led by scientists Heather Christofk and William Lowry, may lead to new drugs that could promote hair growth for people with baldness or alopecia, which is hair loss associated with such factors as hormonal imbalance, stress, aging or chemotherapy treatment.
Scientists have successfully regenerated cells in the retina of adult mice at the University of Washington School of Medicine in Seattle. Their results raise the hope that someday it may be possible to repair retinas damaged by trauma, glaucoma and other eye diseases.
A groundbreaking advancement in materials from Northwestern University could potentially help patients requiring stem cell therapies for spinal cord injuries, stroke, Parkinson’s disease, Alzheimer’s disease, arthritic joints or any other condition requiring tissue regeneration, according to a new study.
Investigators from Brigham and Women’s Hospital (BWH) and the Harvard Stem Cell Institute have a potential solution for how to kill tumor cells that have metastasized to the brain. The team has developed cancer-killing viruses that can deliver stem cells via the carotid artery, and applied them to metastatic tumors in the brain of clinically relevant mouse models. The investigators report the elimination of metastatic skin cancer cells from the brain of these preclinical models, resulting in prolonged survival.
A groundbreaking randomized clinical trial (RCT) evaluating the use of a patient’s own stem cells to regenerate knee cartilage is underway at Andrews Institute for Orthopaedics & Sports Medicine in Gulf Breeze, Florida. The study, led by Adam Anz, M.D., an orthopedic surgeon at Andrews Institute, is the first multicenter Phase II United States Food and Drug Administration (FDA) observed RCT of its kind.